MedTrace Logo

Additive Effect of Endonase on Eradication Rate of First Line Therapy for Helicobacter Pylori

NCT01645761 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2014-01-22

No results posted yet for this study

Summary

Endonase, a kind of protease, is known to cause both extensive degradation of mucins and a reduction in mucus viscosity. As part of the search for more effective forms of therapy against H. pylori when it colonizes not only the surface of the surface mucosal cells but also the surface mucous gel layer covering the mucosal surface of the stomach. The investigators decided to investigate whether or not endonase might have additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori.

Conditions

  • Gastric Ulcer Associated With Helicobacter Pylori

Interventions

DRUG

Endonase

PPI- based triple therapy with endonase

Sponsors & Collaborators

  • Chuncheon Sacred Heart Hospital

    lead OTHER

Principal Investigators

  • Jin Bong Kim, MD · Department of Internal Medicine, Hallym university college of medicine

  • Yeon Soo Kim, MD, PhD. · Department of Internal Medicine, Hallym University College of Medicine

  • Chang Seok Bang, MD · Department of Internal Medicine, Hallym University of College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01645761 on ClinicalTrials.gov